Editorial: Risankizumab in Refractory Crohn's Disease—From Real‐World Effectiveness to Strategic Positioning and Early Monitoring
Abstract
Current therapeutic options for Crohn's disease (CD) continue to evolve, but managing highly refractory patients remains a clinical challenge.Selective interleukin-23 (IL-23) p19 inhibitors, such as risankizumab, have emerged as highly efficacious options in clinical trials [1,2].Translating controlled trial data into day-to-day practice requires confirmation by robust, largescale real-world evidence (RWE) [3].The RISANCROHN study is the largest RWE-generating cohort of risankizumab in CD to date and provides important insights into patient outcomes and treatment positioning [4].
Fields of Study & Subjects
Inflammatory Bowel Disease
Biosimilars and Bioanalytical Methods
Rheumatoid Arthritis Research and Therapies
Publication details
- Journal / source
- Alimentary Pharmacology & Therapeutics
- Volume
- 64
- Issue
- 6
- Pages
- 837–838
- Publication date
- 13 July 2026
- Language
- EN